Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Penicillin G Sodium

FDA-approved product (injectable, injection), marketed as Bicillin, Bicillin L-A, Permapen and 14 more.

Registered studies
50+
Lab records
18
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Penicillin G Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase sensitive penicillins; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CE01; WHO ATC J01CE08; WHO ATC J01CE09; WHO ATC S01AA14

Repurposing investigation

Penicillin G Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA76.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 10 lab records
  • E. coli: measured active in 2 of 4 lab records
  • K. pneumoniae: measured active in 0 of 4 lab records
Open Penicillin G Sodium in ChEMBL Registered studies below
Show the 18 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Penicillin G Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Aminoglycosides in Early Sepsis

    NCT06712641 · start 2026-04-23

    Registered record
    Registry ID
    NCT06712641
    Conditions
    Sepsis
    Interventions
    Gentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-23
    Completion
    2033-05
    Enrolment
    1,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionGentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    PhasePhase 4
    Registry statusRecruiting

  • Antibiotic Prophylaxis Versus Placebo in Alveolar Bone Grafting: A Randomized Controlled Trial

    NCT07296302 · start 2026-02

    Registered record
    Registry ID
    NCT07296302
    Conditions
    Alveolar Ridge Augmentation; Bone Grafting; Antibiotic Prophylaxis
    Interventions
    Amoxicillin 500 mg (prophylactic regimen); Placebo Capsule (matched dosing schedule)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2027-08
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlveolar Ridge Augmentation; Bone Grafting; Antibiotic Prophylaxis
    InterventionAmoxicillin 500 mg (prophylactic regimen); Placebo Capsule (matched dosing schedule)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication

    NCT07115173 · start 2025-12-01

    Registered record
    Registry ID
    NCT07115173
    Conditions
    Helicobacter Infection
    Interventions
    This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2027-12-31
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Infection
    InterventionThis study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
    PhasePhase 4
    Registry statusNot yet recruiting

  • Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

    NCT05870683 · start 2023-05-24

    Registered record
    Registry ID
    NCT05870683
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tegoprazan; Amoxicillin; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-05-24
    Completion
    2023-12-30
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTegoprazan; Amoxicillin; Esomeprazole
    PhaseNot applicable
    Registry statusUnknown

  • The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation

    NCT04552080 · start 2022-12-29

    Registered record
    Registry ID
    NCT04552080
    Conditions
    Patients Undergoing Oral Implant Therapy
    Interventions
    Amoxicillin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-12-29
    Completion
    2026-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Undergoing Oral Implant Therapy
    InterventionAmoxicillin; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

    NCT05302531 · start 2022-12-09

    Registered record
    Registry ID
    NCT05302531
    Conditions
    Short Bowel Syndrome; Infection, Bacterial
    Interventions
    Amoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole trimethoprim
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-12-09
    Completion
    2025-02
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShort Bowel Syndrome; Infection, Bacterial
    InterventionAmoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole trimethoprim
    PhasePhase 1
    Registry statusUnknown

  • One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL

    NCT05728424 · start 2022-09-20

    Registered record
    Registry ID
    NCT05728424
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan, Amoxicillin, Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-09-20
    Completion
    2023-05-01
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan, Amoxicillin, Levofloxacin
    PhasePhase 3
    Registry statusUnknown

  • Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication

    NCT05469685 · start 2022-08-01

    Registered record
    Registry ID
    NCT05469685
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan; Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2023-09-30
    Enrolment
    914

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan; Amoxicillin
    PhasePhase 4
    Registry statusCompleted

  • Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

    NCT05432115 · start 2022-06-25

    Registered record
    Registry ID
    NCT05432115
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Tetracyclin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-06-25
    Completion
    2023-10
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionTetracyclin
    PhasePhase 4
    Registry statusUnknown

  • Collaborative Urological Prosthetics Investigation Directive Research Group

    NCT05100654 · start 2022-04-22

    Registered record
    Registry ID
    NCT05100654
    Conditions
    Erectile Dysfunction; Penile Prosthesis Infection
    Interventions
    Doxycycline; Ciprofloxacin; Augmentin; Bactrim
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2022-04-22
    Completion
    2028-01-01
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Penile Prosthesis Infection
    InterventionDoxycycline; Ciprofloxacin; Augmentin; Bactrim
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • Alternative Antibiotics for Syphilis

    NCT05069974 · start 2021-10-14

    Registered record
    Registry ID
    NCT05069974
    Conditions
    Early Latent Syphilis; Primary Syphilis; Secondary Syphilis
    Interventions
    Linezolid 600 mg (post-interim); Benzathine Penicilllin G (post-interim)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-10-14
    Completion
    2026-04-15
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Latent Syphilis; Primary Syphilis; Secondary Syphilis
    InterventionLinezolid 600 mg (post-interim); Benzathine Penicilllin G (post-interim)
    PhasePhase 3
    Registry statusCompleted

  • Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

    NCT04901117 · start 2021-06

    Registered record
    Registry ID
    NCT04901117
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06
    Completion
    2023-08
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 more
    PhasePhase 4
    Registry statusUnknown

  • RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

    NCT04514653 · start 2020-08-25

    Registered record
    Registry ID
    NCT04514653
    Conditions
    Neovascular Age-Related Macular Degeneration (nAMD)
    Interventions
    Ranibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3; Local Steroid; Topical Steroid; ABBV-RGX-314 Dose 4
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-08-25
    Completion
    2027-02
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeovascular Age-Related Macular Degeneration (nAMD)
    InterventionRanibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3 +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

    NCT04879030 · start 2020-01-01

    Registered record
    Registry ID
    NCT04879030
    Conditions
    COPD Exacerbation Acute
    Interventions
    Beta-Lactams; Fluoroquinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2020-12-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD Exacerbation Acute
    InterventionBeta-Lactams; Fluoroquinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia

    NCT04041791 · start 2019-08-19

    Registered record
    Registry ID
    NCT04041791
    Conditions
    Pneumonia
    Interventions
    Benzyl penicillin; Gentamicin Sulfate; Ceftriaxone; Amoxicillin Clavulanate; Intravenous fluid; Nasogastric feeds; Ampicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-19
    Completion
    2024-04-05
    Enrolment
    4,392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionBenzyl penicillin; Gentamicin Sulfate; Ceftriaxone; Amoxicillin Clavulanate +3 more
    PhasePhase 3
    Registry statusCompleted